Personalized Radiation Therapy for GBM
Study Details
Study Description
Brief Summary
The study is a pilot study to estimate the efficacy of personalized dose-escalation radiation therapy in patients with glioblastoma, as measured by estimating the median of progression-free survival. Toxicity, patterns of recurrence, and overall median survival will be measured as secondary endpoints. Adverse events will be monitored.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Single Arm Dose-escalated radiation therapy |
Radiation: Radation Therapy
Personalized Radiation Therapy
|
Outcome Measures
Primary Outcome Measures
- Adverse Events [2 years]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with biopsy-proven WHO Grade IV glioblastoma, after gross-total or near-total resection, who are undergoing definitive chemoradiation as part of their treatment regimen
-
Age 18 or older
-
Ability to give signed informed consent
-
Karnofsky Performance Status (KPS) at least 70
Exclusion Criteria:
-
Placement of Gliadel wafers
-
Participation in another investigational trial
-
Active treatment of another malignancy
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Abramson Cancer Center of the University of Pennsylvania | Philadelphia | Pennsylvania | United States | 19104 |
Sponsors and Collaborators
- Abramson Cancer Center of the University of Pennsylvania
Investigators
- Principal Investigator: Robert Lustig, MD, Abramson Cancer Center of the University of Pennsylvania
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- UPCC 24317